The DOI matches its Crossref record; 234 of the 234 references it cites were found in a registry or an index.
Epidemiology of Obesity and Pharmacologic Treatment Options
Abstract
Prevalence of obesity and its related morbidity have increased to alarming levels in adults and children in the United States and globally. Weight loss results in improvement of much of the obesity‐related morbidity. Lifestyle changes such as dietary modifications, increased physical activity, and behavioral therapy form the crux of weight management. However, many individuals need additional assistance (pharmacologic or surgical) to initiate or sustain weight loss. Pharmacologic therapy consists of a number of agents that work by decreasing appetite, gastric emptying, or nutrient absorption or by increasing satiety. Five classes of drug are currently approved for adults, including sympathomimetics (with and without an antiepileptic agent topiramate), gastrointestinal lipase inhibitors, serotonin agonists, glucagon‐like peptide 1 agonists, and antidepressant/opioid antagonist combination. Pharmacologic options for children with obesity are minimal (lipase inhibitor orlistat is the only approved medication for children aged >12 years); however, all adult medications are approved by the Food and Drug Administration for children aged >16 years old. While side effect profiles of these medications are far superior to older medications, their use is limited by lack of long‐term cardiovascular safety data, costs of medications and variable insurance coverages, and the need for continued usage for sustainable benefits. Weight loss medications may induce complacence, on part of both the patient and the provider, regarding lifestyle modifications, without which the drug therapy is almost certain to be of minimal benefit. Several novel drugs are in the pipeline targeting brown fat, energy expenditure, appetite suppression, and satiety.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Certain anti-obesity drugs, including selective serotonin reuptake inhibitors and naltrexone/bupropion combinations, have been linked to adverse psychological outcomes such as mood alterations and suicidal ideation [69].”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [69]
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 1×
“Loss of 5%–7% of one’s body weight can provide meaningful reduction in cardiovascular disease risk factors and is achievable for most patients.(18,19,26) However, patients often expect much higher percentages of weight loss that are unrealistic, and these expectations may be counterproductive during the active weight…”
BackgroundNg, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., Mullany, E. C., Biryukov, S., Abbafati, C., Abera, S. F., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60460-8 · Cited by 11,952
Prevalence of Childhood and Adult Obesity in the United States, 2011-2012
Ogden, C. L., Carroll, M. D., Kit, B. K., & Flegal, K. M. (2014) · JAMA · doi:10.1001/jama.2014.732 · Cited by 8,072
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Prevalence of Obesity Among Adults and Youth: United States, 2015-2016.
Hales, C. M., Carroll, M. D., Fryar, C. D., & Ogden, C. L. (2017) · PubMed · Cited by 3,889
Annual Medical Spending Attributable To Obesity: Payer-And Service-Specific Estimates
Finkelstein, E. A., Trogdon, J. G., Cohen, J. W., & Dietz, W. H. (2009) · Health Affairs · doi:10.1377/hlthaff.28.5.w822 · Cited by 2,956
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Changes in Energy Expenditure Resulting from Altered Body Weight
Leibel, R. L., Rosenbaum, M., & Hirsch, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321001 · Cited by 2,012
Research works printed but not linked: 3
- Dobbs R, 2015, The Global Obesity Threat
- Ryan DA. B, 2014, Handbook of Obesity, 233
- 2 new drugs for weight loss, 2012, Med Lett Drugs Ther, 54, 69
Cited by
Sorted by citations
A review of current guidelines for the treatment of obesity
(2022) · The American Journal of Managed Care · doi:10.37765/ajmc.2022.89292 · Cited by 207
Obesity in South and Southeast Asia—A new consensus on care and management
Tham, K. W., Abdul Ghani, R., Cua, S. C., Deerochanawong, C., Fojas, M., Hocking, S., Lee, J., Nam, T. Q., Pathan, F., Saboo, B., et al. (2023) · Obesity Reviews · doi:10.1111/obr.13520 · Cited by 187
Pediatric obesity: Current concepts
Greydanus, D. E., Agana, M. G., Kamboj, M. K., Shebrain, S., Soares, N. S., Eke, R., & Patel, D. R. (2018) · Disease-a-Month · doi:10.1016/j.disamonth.2017.12.001 · Cited by 104
Guirguis, A., Chiappini, S., P, G. P., Vickers‐Smith, R., Harris, D. R., Corkery, J., Arillotta, D., Floresta, G., Martinotti, G., & Schifano, F. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.02.003 · Cited by 79
Sharma, R., Matsuzaka, T., Kaushik, M. K., Sugasawa, T., Ohno, H., Wang, Y., Motomura, K., Shimura, T., Okajima, Y., Mizunoe, Y., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41631-1 · Cited by 67
Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning
Kim, J. A., & Yoo, H. J. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0242 · Cited by 71
“Certain anti-obesity drugs, including selective serotonin reuptake inhibitors and naltrexone/bupropion combinations, have been linked to adverse psychological outcomes such as mood alterations and suicidal ideation [69].”
Update on childhood/adolescent obesity and its sequela
Kohut, T. J., Robbins, J., & Panganiban, J. A. (2019) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000786 · Cited by 52
Yi, D. Y., Kim, S. C., Lee, J. H., Lee, E. H., Kim, J. Y., Kim, Y. J., Kang, K. S., Hong, J., Shim, J. O., Lee, Y. M., et al. (2018) · Korean Journal of Pediatrics · doi:10.3345/kjp.2018.07360 · Cited by 47
Yi, D. Y., Kim, S. C., Lee, J. H., Lee, E. H., Kim, J. Y., Kim, Y. J., Kang, K. S., Hong, J., Shim, J. O., Lee, Y. M., et al. (2019) · Pediatric Gastroenterology Hepatology & Nutrition · doi:10.5223/pghn.2019.22.1.1 · Cited by 33
Accacha, S. D., Barillas, J., Srivastava, A., Ross, F., Drewes, W., Gulkarov, S., Leon, J. D., & Reiss, A. B. (2025) · Metabolites · doi:10.3390/metabo15050287 · Cited by 33
Novel microencapsulated probiotic blend for use in metabolic syndrome: design and in-vivo analysis
Iqbal, U. H., Westfall, S., & Prakash, S. (2018) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2018.1489270 · Cited by 25
Concurrent Laparoscopic Ventral Hernia Repair with Bariatric Surgery: a Propensity-Matched Analysis
Moolla, M., Dang, J. T., Modasi, A., Byrns, S., Switzer, N. J., Birch, D. W., & Karmali, S. (2019) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-019-04291-0 · Cited by 24
Jincheng, L., Xiong, F., Yao, J., Dai, X., Yulei, L., Hu, M., Zhang, L., & Li, Y. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/3039783 · Cited by 23
Inducible nitric oxide synthase‐derived nitric oxide reduces vagal satiety signalling in obese mice
Yu, Y., Park, S. J., & Beyak, M. J. (2018) · The Journal of Physiology · doi:10.1113/jp276894 · Cited by 16
Identification of Digestive Enzyme Inhibitors from Ludwigia octovalvis (Jacq.) P.H.Raven
Morales-Ferra, D. L., Ramírez, G., Herrera-Arellano, A., Tortoriello, J., Zavala-Sánchez, M. Á., & Zamilpa, A. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/8781352 · Cited by 16
Cheon, C., Song, Y.-K., & Ko, S. (2020) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2020.102423 · Cited by 14
Lhamyani, S., Gentile, A., Mesa, M. M., Grueso, E., Giráldez‐Pérez, R. M., Fernández‐García, J. C., Vega, A. P., Clemente‐Postigo, M., Pearson, J. R., González‐Mariscal, I., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116104 · Cited by 7
Kohut, T. J., Serai, S. D., & Panganiban, J. A. (2021) · JPGN Reports · doi:10.1097/pg9.0000000000000126 · Cited by 5
Lou, K., Huang, P. C., Ma, H., Wang, X., Xu, H., & Wang, W. (2019) · Drug and Chemical Toxicology · doi:10.1080/01480545.2019.1683571 · Cited by 4
Gu, D.-Q., Li, Y., Wu, L., Lyu, M.-T., Li, Y., Huang, S.-Z., Xu, F.-Q., Wu, D., & Zhou, W.-X. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00264h · Cited by 3
Bariatric Surgery in Adolescents
Lamoshi, A. Y., Chen, M., Majumdar, I., & Harmon, C. M. (2020) · Current Treatment Options in Pediatrics · doi:10.1007/s40746-020-00196-2 · Cited by 3
Farmacoterapia da obesidade: fármacos disponíveis no Brasil e perfis de eficácia e segurança
Utta, K. B., & Pessoa, D. (2021) · Research, Society and Development · doi:10.33448/rsd-v10i12.18829 · Cited by 2
Wang, B., Wu, J., & Zhang, T. (2026) · Food Research International · doi:10.1016/j.foodres.2026.119124 · Cited by 1
Obesity in Children/Adolescents and Obesity-Related Comorbidities
Kohut, T. J., Robbins, J., Prout, E. P., Katz, L. E. L., Brothers, J. A., Vazquez-Diaz, S., Genuario, K., & Panganiban, J. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-53370-0_27 · Cited by 1
Bariatric Surgery in Adolescents
Dorman, R. M., Mehaffey, J. H., & Harmon, C. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-43642-5_47
Mitchell, T. B., & Janicke, D. M. (2018) · Springer eBooks · doi:10.1007/978-3-030-00791-1_4
The Dark Side of GLP-1 Receptor Agonists: Risks and Adverse Events
Nawal, C. L., Saini, H. L., Rankawat, G., & Chejara, R. S. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1655
Metadata
- Authors
- Shettar, V., Patel, S., & Kidambi, S.
- Affiliations
- Medical College of Wisconsin (US)
- Corresponding author
- Kidambi, Srividya
- ORCID
- Kidambi, Srividya
- Venue
- Nutrition in Clinical Practice
- Publisher
- Wiley
- Published
- 2017-06-20
- Volume
- 32
- Issue
- 4
- Pages
- 441-462
- ISSN
- 0884-5336 (ISSN-L)
- 1941-2452
- OpenAlex
- W2628165181
- Cited by
- 26
- References
- 234
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 2 · 2022: 1 · 2021: 2 · 2020: 3 · 2019: 5 · 2018: 7
- FWCI
- 0.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Nutrition in Clinical Practice (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- obesity, obesity pharmacotherapy, anti-obesity drugs, obesity prevalence, childhood obesity, sympathomimetic drugs, topiramate, lipase inhibitors, orlistat, serotonin receptor agonists, GLP-1 receptor agonists, lifestyle modification, brown adipose tissue, energy expenditure, adverse drug reactions, cardiovascular safety, obesity-related morbidity
- MeSH terms
- Diet, Energy Metabolism, Humans, Life Style, Obesity, United States, United States Food and Drug Administration, Meta-Analysis as Topic, Weight Loss, Exercise, Randomized Controlled Trials as Topic, Anti-Obesity Agents, Disease Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
